Applied Genetic Technologies Corpor... (AGTC)


+0.01 (+2.55%)
Symbol AGTC
Price $0.2778
Beta 1.260
Volume Avg. 1.37M
Market Cap 18.788M
Shares () -
52 Week Range 0.256-3.18
1y Target Est -
DCF Unlevered AGTC DCF ->
DCF Levered AGTC LDCF ->
ROE 0.20% Neutral
ROA 0.15% Neutral
Operating Margin -
Debt / Equity 126.22% Buy
P/E -
P/B 0.42 Neutral


Consensus EPS

Upgrades & Downgrades

Latest AGTC news

Ms. Susan Washer
NASDAQ Global Market

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.